Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: "Recently published papers: Novel therapies in chronic obstructive pulmonary disease, cardiac chemicals and intensive care outcomes"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: Recently published papers: Novel therapies in chronic obstructive pulmonary disease, cardiac chemicals and intensive care outcomes. | Available online http ccforum.eom content 13 5 198 Commentary Recently published papers Novel therapies in chronic obstructive pulmonary disease cardiac chemicals and intensive care outcomes Uma M Bandarupalli and Gareth D Williams Adult Critical Care Unit Leicester Royal Infirmary Leicester LE1 5WW UK Corresponding author Gareth D Williams gareth.williams@uhl-tr.nhs.uk Published 27 October 2009 This article is online at http ccforum.com content 13 5 198 2009 BioMed Central Ltd Critical Care 2009 13 198 doi 10.1186 cc8130 Abstract The burden of chronic obstructive pulmonary disease on intensive care is heavy but newer modalities of treatment are now available to improve outcomes. Cardiac-based research continues to generate new drugs and tests to better outcome and aid in early diagnosis. And how do various intensive care interventions compare in improving clinical and functional outcomes Novel therapies in chronic obstructive pulmonary disease Chronic obstructive pulmonary disease COPD continues to be a major medical problem. With no curative therapy being available management of severe exacerbations of COPD should be directed at relieving symptoms and restoring functional capacity 1 . Mortality from COPD continues to rise and the World Health Organisation predicts it will be the third leading cause of death by 2030 2 . There is current evidence suggesting that quality improvement interventions ought to be focussed at recognition of complications and treatment of the same 3 . We examine a randomized double-blind cross-over study published by Israeli investigators Staz and Rav 4 looking at the effect of N-acetylcysteine NAC on airflow limitation in COPD. Twenty-four moderate to severe COPD patients were randomized to placebo or nebulised NAC 1 200 mg per day treatment twice daily for 6 weeks. This was followed by a 2-week washout period and patients were crossed over to alternative therapy for a further 6 weeks. Evaluation of forced vital capacity inspiratory .